INGN 250117 7.50C (INGN250117C7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

INGN250117C7500

Watchlist

1.78
+0.08+4.71%

15min DelayClose Jan 3 16:00 ET

1.78High1.78Low

Intraday

5D
Daily

News

Inogen Expands U.S. Market With FDA Clearance
Yahoo FinanceDec 31, 2024 08:58 ET
Sector Update: Health Care Stocks Softer Late Afternoon
MT NewswiresDec 30, 2024 15:56 ET
Sector Update: Health Care
MT NewswiresDec 30, 2024 15:30 ET
Express News | Inogen Inc - Plans to Pursue Limited Launch of Simeox 200 in 2025
ReutersDec 30, 2024 08:31 ET
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device
BusinesswireDec 30, 2024 08:30 ET
Express News | Inogen Receives FDA 510(K) Clearance for Simeox 200 Airway Clearance Device
ReutersDec 30, 2024 08:30 ET

Comments

Jaguar8

Dec 30, 2024 18:43

NEWS TODAY

$Inogen (INGN.US)$
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device
Monday, 30th December at 8:30 am
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company's ability to market and meet the various needs of patients with chronic...

Trytosaveabit

Aug 6, 2024 15:41

Hmm

$Inogen (INGN.US)$
Second Quarter 2024 Financial Results
Second quarter total revenue increased 6.1% to $88.8 million from $83.6 million in the second quarter of 2023, primarily driven by higher demand and new customers in international and domestic business-to business sales, partially offset by lower direct-to-consumer sales and rental revenue.
Total gross margin was 48.1% in the second quarter of 2024 versus 40.7% in the comparative period in 2023. The increase was driven primarily by low...

Moomoo AI

Feb 9, 2024 05:21

Investors' belief that strong revenue growth is not on the horizon for Inogen contributes to its low P/S ratio. The company's underwhelming revenue outlook is a major factor. A change of fortune is needed to justify a higher P/S in the future.

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

$Inogen (INGN.US)$ @Rivera this one worth adding and waiting?